<unk>  is a isocitrate dehydrogenase-2 inhibitor that is FDA approved for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test. There is a Black Box Warning for this drug as shown here.  Common adverse reactions include nausea, vomiting, diarrhea, elevated bilirubin, and decreased appetite.
Enasidenib
Ivosidenib
Brigatinib
Fostamatinib
Toceranib
Lorlatinib
Dabrafenib mesylate
Neratinib